NPTX2, also known as neuronal activity-regulated protein, has been reported to have reduced CSF levels in various neurodegenerative diseases such as AD (22), genetic frontotemporal dementia (FTD) (23), and dementia with Lewy bodies (DLB) (24), correlating with cerebral atrophy and cognitive dysfunction (33). This evidence concerns the gene NPTX2 and frontotemporal dementia.